Documento de posicionamiento de la Asociación Española de Urología (AEU) y su Grupo de Urología Oncológica (GUO) sobre la prescripción de inhibidores de PARP (iPARP) en el cáncer de próstata resistente a la castración metastásico

IF 1.7 4区医学 Q3 UROLOGY & NEPHROLOGY

Actas urologicas espanolas Pub Date : 2026-03-01 Epub Date: 2025-12-18 DOI:10.1016/j.acuro.2025.501898

C. González Enguita , D. Pérez Fentes , A. Budía Alba , M.F. Lorenzo Gómez , J. Gómez Rivas , C. Manso Aparicio , T. Fernández Aparicio , J.L. Alvárez-Ossorio Fernández , en representación de la Junta Directiva AEU (Asociación Española de Urología), del GUO (Grupo de Urología Oncológica) y del Patronato Rector de la FIU (Fundación para la Investigación en Urología)

{"title":"Documento de posicionamiento de la Asociación Española de Urología (AEU) y su Grupo de Urología Oncológica (GUO) sobre la prescripción de inhibidores de PARP (iPARP) en el cáncer de próstata resistente a la castración metastásico","authors":"C. González Enguita , D. Pérez Fentes , A. Budía Alba , M.F. Lorenzo Gómez , J. Gómez Rivas , C. Manso Aparicio , T. Fernández Aparicio , J.L. Alvárez-Ossorio Fernández , en representación de la Junta Directiva AEU (Asociación Española de Urología), del GUO (Grupo de Urología Oncológica) y del Patronato Rector de la FIU (Fundación para la Investigación en Urología)","doi":"10.1016/j.acuro.2025.501898","DOIUrl":null,"url":null,"abstract":"<div><div>In recent months, restrictions have been proposed on the prescription of PARP inhibitors (iPARP) by urologists in metastatic castration-resistant prostate cancer (mCRPC). The Spanish Association of Urology (AEU), its Uro-Oncology Group (GUO), and the presidents of the Regional Urology Associations consider these limitations unjustified from clinical, organizational, legal, or professional perspectives. They unduly restrict the exercise of competencies recognized in the interdisciplinary management of prostate cancer, in line with the training, experience, and current regulations of the specialty. This document argues, from scientific, clinical, and legal standpoints, that urologists are qualified and legally authorized to prescribe and administer iPARP according to current legislation and the official training program. It also advocates a collaborative model centred on the patient's care pathway and based on mutual respect among specialties, ensuring professional autonomy, continuity of care, and equitable access to therapeutic innovation.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501898"},"PeriodicalIF":1.7000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0210480625002165","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In recent months, restrictions have been proposed on the prescription of PARP inhibitors (iPARP) by urologists in metastatic castration-resistant prostate cancer (mCRPC). The Spanish Association of Urology (AEU), its Uro-Oncology Group (GUO), and the presidents of the Regional Urology Associations consider these limitations unjustified from clinical, organizational, legal, or professional perspectives. They unduly restrict the exercise of competencies recognized in the interdisciplinary management of prostate cancer, in line with the training, experience, and current regulations of the specialty. This document argues, from scientific, clinical, and legal standpoints, that urologists are qualified and legally authorized to prescribe and administer iPARP according to current legislation and the official training program. It also advocates a collaborative model centred on the patient's care pathway and based on mutual respect among specialties, ensuring professional autonomy, continuity of care, and equitable access to therapeutic innovation.

查看原文本刊更多论文

西班牙泌尿学协会（AEU）及其泌尿学肿瘤学小组（GUO）关于对转移性阉割耐药前列腺癌使用PARP抑制剂（iPARP）的立场文件

近几个月来，泌尿科医生对转移性去势抵抗性前列腺癌（mCRPC）的PARP抑制剂（iPARP）处方提出了限制。西班牙泌尿外科协会（AEU）、其泌尿肿瘤学小组（GUO）和地区泌尿外科协会主席认为，从临床、组织、法律或专业角度来看，这些限制是不合理的。他们不恰当地限制了前列腺癌跨学科管理中公认的能力的行使，这与该专业的培训、经验和现行法规是一致的。本文件从科学、临床和法律的角度认为，根据现行立法和官方培训计划，泌尿科医生有资格并被合法授权开处方和管理iPARP。它还倡导以患者的护理途径为中心，在各专科相互尊重的基础上建立合作模式，确保专业自主、护理的连续性和公平获得治疗创新。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Actas urologicas espanolas UROLOGY & NEPHROLOGY-

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

46 days

期刊介绍： Actas Urológicas Españolas is an international journal dedicated to urological diseases and renal transplant. It has been the official publication of the Spanish Urology Association since 1974 and of the American Urology Confederation since 2008. Its articles cover all aspects related to urology. Actas Urológicas Españolas, governed by the peer review system (double blinded), is published online in Spanish and English. Consequently, manuscripts may be sent in Spanish or English and bidirectional free cost translation will be provided.